Loading...
Loading...
NeoStem, Inc.
NBS and its subsidiary, Progenitor Cell Therapy LLC
("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively,
"Adaptimmune"), announced today a Services Agreement under which PCT will
provide services to support Adaptimmune's NYESO-1^c259-T cell therapy product
being developed for multiple oncology indications (for more information with
respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers
NCT01350401, NCT01343043 and NCT01352286).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in